Mantle in Medical News

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

... which are rare diseases. A member of LRF's mantle Cell Lymphoma Consortium (MCLC), Dr. Fu's work will focus on mantle cell lymphoma (MCL), an aggressive malignant B-cell form of non-Hodgkin lymphoma (NHL). mantle cell lymphoma is a rare form of NHL accounting ...

Pitt, Berkeley researchers reconstruct seashells to model nervous system function

... with a mollusk's tongue-like organ called a mantle and leads to the cells that produce the shell and ... shells, they retrace their previous work with the mantle and use those "memories" to continue the pattern. ... the neurons connecting the sensing cells in the mantle with the secretory cells that produce calcium ...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and ...

Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years

... SAN FRANCISCO - More than half of younger mantle cell lymphoma patients who received an intensive ... necessary as a first treatment in newly diagnosed mantle cell lymphoma." mantle cell lymphoma is one of the most lethal versions ...

Novel treatments show improvements in survival and response rates for leukemia and lymphoma

... lymphocytic lymphoma (11 patients), mantle cell lymphoma (nine patients), MALT lymphoma ... lymphocytic lymphoma, 11 percent of mantle cell lymphoma patients, and 10 percent of those ... with diffuse large B-cell lymphoma, four with mantle cell lymphoma, two with chronic lymphocytic ...

Novel Treatments Demonstrate Improvements in Overall Survival and Response Rates in Difficult-To-Treat Forms of Leukemia and Lymphoma

... lymphocytic lymphoma (11 patients), mantle cell lymphoma (nine patients), MALT lymphoma ... lymphocytic lymphoma, 11 percent of mantle cell lymphoma patients, and 10 percent of those ... with diffuse large B-cell lymphoma, four with mantle cell lymphoma, two with chronic lymphocytic ...

Researchers aim to over-stress already taxed mantle cell lymphoma cells

... can disrupt the over-stressed assembly line of mantle cell lymphoma and possibly similar cancers such ... mechanism for eliminating poorly made ones. mantle cell lymphoma, an aggressive cancer of the ... sink won't work with a clogged garbage disposal, mantle cell lymphoma cells will start backing up. When a ...

VCU Massey Cancer Center spearheads novel clinical study for lymphoma patients

... patients with diffuse large B-cell lymphoma, or mantle cell lymphoma. The study is intended for patients ... important classes of new agents." Within the mantle cell lymphoma patient group, the study will ... treatment of patients with relapsed or refractory mantle cell lymphoma, and previously was approved for ...

Incidence of Mantle Cell Lymphoma on Rise

... July 18 (HealthDay News) -- The prevalence of mantle cell lymphoma, an aggressive form of non-Hodgkin ... of Texas M.D. Anderson Cancer Center. mantle cell lymphoma is a fast-growing, incurable cancer ... The study authors found that the incidence of mantle cell lymphoma increased from 2.7 people per one ...

FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma

... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and ...

VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial

... is indicated for the treatment of patients with mantle cell lymphoma who have received at least one ... of peripheral neuropathy has not been studied in mantle cell lymphoma. Acute development or exacerbation ... was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, ...

Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients

... therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma

... one prior therapy. VELCADE is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is ... profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported ...

Sports Icons Troy Aikman, Clyde Drexler, Mike Piazza, Ivan Lendl and Dara Torres are Among the Elite Named 2009 'Great Sports Legends'

... Miami Project's spinal cord injury research programs. Legend and Honoree Alumni include Michael Jordan , Muhammad Ali , Jack Nicklaus , Mickey mantle , Wayne Gretzky , Lance Armstrong , John Elway , Helio Castroneves , Earvin "Magic" Johnson , Joe DiMaggio, Dan Marino , Tommy Lee Jones, ...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

... Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial II-44 FDA Grants Approval for Use of VELCADE(R) for Patients with mantle Cell Lymphoma II-44 4. Recent Industry Activity II-45 CytRx to Acquire Innovive II-45 Launch of Epoetin alfa Hexal II-45 PDL and ...

Make No Small Plans: M. D. Anderson Cancer Center Endeavors to Make Cancer History

... A. "Mickey" LeMaistre, M. D., was appointed in 1962 to the first U.S. Surgeon General's Advisory Committee on Smoking and Health, picked up the mantle in 1978 and served for 18 years. He was at the center of a powerful public health movement that awakened the nation to cancer prevention and ...

Healthcare Businesswomen's Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company

... science. It has been prescribed to more than 100,000 people in 87 countries worldwide, treating patients with multiple myeloma and relapsed mantle cell lymphoma, a sub-type of non-Hodgkin's lymphoma. Dr. Dunsire presided over Millennium's acquisition by Takeda Pharmaceutical Company Limited in ...

Green tea may negate the effects of a common cancer therapy

... myeloma, a blood cancer, and glioblastoma, a malignant brain tumor. Bortezomib, an anticancer therapy approved to treat multiple myeloma and mantle cell lymphoma, normally fights disease by inhibiting proteasomes and inducing tumor cell death. However, in both in vitro and in vivo mouse ...

USC study finds that green tea blocks benefits of cancer drug

... at the University of Southern California (USC) have found that the widely used supplement renders a cancer drug used to treat multiple myeloma and mantle cell lymphoma completely ineffective in treating cancer. The study, which found that a component of green tea extract (GTE) called EGCG destroys ...

Green Tea May Negate the Effects of a Common Cancer Therapy

... multiple myeloma, a blood cancer, and glioblastoma, a malignant brain tumor. Bortezomib, an anticancer therapy approved to treat multiple myeloma and mantle cell lymphoma, normally fights disease by inhibiting proteasomes and inducing tumor cell death. However, in both in vitro and in vivo mouse ...

Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL

... 6 55% - MCL 9 1 11% * Other NHL patients included 11 with CLL/SLL, 9 with mantle cell NHL, 1 with Lymphoplasmacytic NHL and 3 with MALT/MZL. The 4 patients with Lymphoplasmacytic and MALT are not referenced in the ...

Possible Cure for Rare Lymphoma Reported

... A complex regimen that included immunochemotherapy produced a five-year, event-free survival rate of better than 60 percent in 159 people with mantle cell lymphoma, physicians at the Rigshospitalet in Copenhagen reported Sunday at the American Society of Hematology annual meeting, in Atlanta. ...

Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients

... data from the ongoing Phase 1 dose-escalating trial show evidence of objective complete and partial responses in relapsed follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL) patients. At the time of the analysis, dose levels tested ranged from 0.0005 to 0.030 ...

Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008

... II Study of R-CHOP Followed by December 10, PM (389) 90Y-Ibritumomab Tiuxetan in Untreated 2007 mantle Cell Lymphoma: Eastern Cooperative Oncology Group Study E1499. Monday, ...

ADHD Delays Growth of Certain Brain Areas

... Health (NIMH). They found that the delay in brain maturation in children with ADHD was most prominent in regions at the front of the brain's outer mantle (cortex), which is involved in thinking, planning and attention. Magnetic resonance imaging (MRI) scans of the brains of 223 children with ADHD ...

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia

... with the intent to treat patients with certain types of B-cell lymphomas. MT103 received orphan drug designation from the EMEA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. In February 2006, the U.S. Food and Drug Administration (FDA) also approved an orphan drug ...

Ten Finalists Chosen for 2007 Hutch Award

... recipient will be selected in mid-November through a vote of all surviving former awardees. Through the years, 42 players have been honored. Mickey mantle accepted the inaugural award in 1965, the year after baseball great Fred Hutchinson (known as "Hutch") succumbed to cancer at age 45. Hall-of-Famers ...

Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia

... in the fourth quarter of 2007. In addition, Cephalon is studying TREANDA in combination with rituximab in patients with relapsed indolent and mantle cell NHL. The company anticipates that results from studies of TREANDA as monotherapy and in combination will be presented at medical meetings later ...

Agra Surgeon Conducts Fifty Operations at One Go

... wife in the surgeries he conducts. The doctor said he was happy that his son, who is also a surgeon at Belgaum, Karnataka, joined him this year. "The mantle and the skill have now been passed on to the generation next." For the past several years Prakash has been performing free non-stop operations ...

MRI Better Than CT for Diagnosing Strokes

... rooms spotted only 25%of strokes and hence have to be replaced by MRI scans which are better in identifying any type of stroke. // “This mantle should now be passed to magnetic resonance imaging,” wrote Dr. Geoffrey A. Donnan and colleagues at the University of Melbourne in Australia in a ...

Health Experts Shocked As 11-year-old Girl To Be UK's Youngest Mother

... The case of an 11-year-old girl who is all set to don the mantle of becoming the youngest mother in UK has shocked and frustrated health experts who maintain// that it is her age to play with dolls and not rear ...

Government Initiatives To Halt Child Obesity, Needs Clarity Of Purpose

... January, which essentially means that youngsters will be assessed not until summer to make the results available only during the next year. The mantle of responsibility belongs to the Department of Health, Department for Education and Skills and the Department for Culture, Media and Sport, which ...

Fungal toxins infected corn the reason for congenital defects

... and Boston University School of Public Health, Boston, MA, and the Medical Institute, Austin, TX were the researchers who took upon themselves the mantle if the study and proved a thought hypothesis. They established the link between corn consumption and NTD outbreak linking it to fungi toxins. ...